Eyeworld

8 EW ASCRS NEWS Technology as part of the Sunday Summit. We select a medical or technology-related talk given by someone other than an ophthal- mologist, and this year we are proud and honored to have John Medina, PhD, who is a best-selling author of numerous books on the brain and how it functions. We can expect a fascinating lecture. One of our favorite sessions of the meeting is the ASCRS Innovators General Session, which features the Kelman Innovator's Award. This year's recipient is Ron Kurtz, MD, for his outstanding work in lasers in ophthalmology. The session will also include five innovative talks on fascinating topics in new technol- ogy in cornea, refractive, cataract and glaucoma surgery. It's always a fascinating session. We wrap up our meeting with one of the sessions that you, Eric, moderate and have run for years. It's called the Best of ASCRS 2019, and this is where you and a few EyeWorld Editorial Board members pick the best presentations from throughout the meeting. I don't know how they do this but in a short period of time they choose and summarize the best papers from the meeting and they are presented to an expert panel for discussion and debate. This session gives a synopsis of the best of the week and is always one of the high- est rated sessions of the meeting. Dr. Donnenfeld: Thanks, Ed. I want to again thank you for all your contributions to ASCRS and to ophthalmology in general. The ASCRS•ASOA Annual Meeting is the most important meeting in the world for anterior segment surgeons and certainly a meeting that every anterior segment surgeon should go to. We are looking forward to seeing everyone in San Diego this May. EW Editors' note: This is an edited tran- script of a conversation between Dr. Donnenfeld and Dr. Holland in January 2019. Contact information Donnenfeld: ericdonnenfeld@gmail.com Holland: eholland@holprovision.com be exciting, fun, and filled with the latest pearls in cataract surgery. We have also expanded our in- structional courses, which are always a big part of our meeting. This year 40% of the courses will be new, so it will be a refreshing change to help bring new ideas. We've expanded our Skills Transfer labs as they are always in high demand. New this year is an exciting program called the Winning Pitch Challenge, co-moderated by Vance Thompson, MD, and myself. In this session, attendees present innova- tive ideas and new technology to a panel of judges. We will be award- ing a $10,000 cash prize to the best innovative idea. Finally, we are presenting Sea- son 2 of The Voice of Ophthalmology where contestants present contro- versial topics and expert "coaches" help them make their case to the audience. What's new for Season 2 is that we asked our members to sub- mit videos and the contestants will be selected from these auditions. Last year we had a standing room only crowd for this exciting session, and we expect the same this year. Dr. Donnenfeld: So wherever you are in your career, there is some- thing at the ASCRS•ASOA Annual Meeting that you can take back home with you and become a better ophthalmologist. Tell me about the Honored Guests this year who are very special. Dr. Holland: We are pleased to rec- ognize Andrew Maxwell, MD, PhD, and Donald Serafano, MD, as the David A. Karcher Honored Guests for 2019. These outstanding oph- thalmologists are being honored for their years of teaching and service with ASCRS. Our Special Guest this year is Hal Kushner, MD, Col. (Ret.). Many of our members may have seen the Ken Burns documentary on Viet- nam, and Dr. Kushner was featured numerous times throughout that nine-part series. He is a true Ameri- can hero and went on to become an ophthalmologist. He is a long-stand- ing ASCRS member and outstand- ing doctor so we wanted to bring his story to our Opening General Session. It's a remarkable story for a remarkable human being. Dr. Donnenfeld: I couldn't agree more. I am looking forward to hearing from Dr. Kushner and our Honored Guests. We also have some special annual lectures. Can you talk about those? Dr. Holland: This year's Binkhorst Lecture will be given by Stephen Pflugfelder, MD, from Baylor University. He's a world-renowned expert in ocular surface disease and dry eye and has advanced the field tremendously in the diagnosis and treatment of dry eye. Then we have our annual Lecture on Science, Medicine and Early continued from page 3 ACRYSOF ® IQ TORIC IOL IMPORTANT PRODUCT INFORMATION CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician. INDICATIONS: The AcrySof ® IQ Toric posterior chamber intraocular lenses are intended for primary implantation in the capsular bag of the eye for visual correction of aphakia and pre-existing corneal astigmatism secondary to removal of a cataractous lens in adult patients with or without presbyopia, who desire improved uncorrected distance vision, reduction of residual refractive cylinder and increased spectacle independence for distance vision. WARNING/PRECAUTION: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Toric IOLs should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary lens repositioning should occur as early as possible prior to lens encapsulation. All viscoelastics should be removed from both the anterior and posterior sides of the lens; residual viscoelastics may allow the lens to rotate. Optical theory suggests that high astigmatic patients (i.e. > 2.5 D) may experience spatial distortions. Possible toric IOL related factors may include residual cylindrical error or axis misalignments. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon for this product informing them of possible risks and benefits associated with the AcrySof ® IQ Toric Cylinder Power IOLs. Studies have shown that color vision discrimination is not adversely affected in individuals with the AcrySof ® Natural IOL and normal color vision. The effect on vision of the AcrySof ® Natural IOL in subjects with hereditary color vision defects and acquired color vision defects secondary to ocular disease (e.g., glaucoma, diabetic retinopathy, chronic uveitis, and other retinal or optic nerve diseases) has not been studied. Do not resterilize; do not store over 45° C; use only sterile irrigating solutions such as BSS ® or BSS PLUS ® Sterile Intraocular Irrigating Solutions. ATTENTION: Reference the Directions for Use labeling for a complete listing of indications, warnings and precautions. © 2018 Novartis 7/18 US-TOR-18-E-1605 February 2019

• Cover